Yonjin Venture

TECLens designs and manufactures medical vision-correction devices centered on a corneal crosslinking lens for myopia treatment and related conditions. The core product is a non-invasive therapy worn for about 30 minutes in a clinician’s waiting room, with the eye open or closed, delivering real-time ultrasound sensing and precise prescription tuning to reshape the cornea. The lens operates in a high-oxygen environment and uses scleral positioning to maintain stability during treatment. It aims to address presbyopia, slow progression of myopia in children, and corrections for keratoconus and other refractive errors, potentially reducing long-term reliance on traditional corrective lenses. The company is based in St. James, New York.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

Intressa Vascular is a medical technology company focused on developing advanced solutions for cardiovascular conditions, particularly aortic dissection. The company utilizes a proprietary braiding technology platform to create multilayer stents designed for endovascular treatment. This innovative approach enables physicians to effectively address the severe impacts of aortic dissections while minimizing the risk of ischemic complications. Through collaborative efforts and a commitment to high-quality product development, Intressa Vascular aims to enhance patient care and improve clinical outcomes in the treatment of cardiovascular diseases.

Bluejay Therapeutics is a private biopharmaceutical company focused on developing curative treatments for infectious and liver diseases. Its initial program targets chronic hepatitis B, a widespread infection with unmet medical need, using two approaches: fully human IgG1 monoclonal antibodies against hepatitis B surface antigen and oral small-molecule inhibitors of HBsAg. The aim is to reduce viral surface antigen and restore adaptive immunity, potentially achieving a functional cure for HBV and enabling patients to regain immune control of infection. The company’s work also contemplates extending its approach to other viral liver diseases, including chronic hepatitis D.

Regenacy Pharmaceuticals is a Boston-based biopharmaceutical company founded in 2016 that develops therapies for peripheral neuropathies, hemoglobinopathies and certain oncology indications. Its approach centers on restoring normal protein function with oral, isoform-selective histone deacetylase inhibitors. The company is advancing drug programs that include ricolinostat to address sickle cell disease and beta-thalassemia, as well as additional HDAC inhibitor–based therapies for neuropathies and related conditions.

OncoResponse is an immuno‑oncology biotechnology company that uses a proprietary human antibody platform to discover novel targets and develop fully human monoclonal antibodies for cancer treatment. By interrogating the adaptive immune system of patients who respond exceptionally well to checkpoint inhibition, the company identifies genuine human antibodies against high‑value targets linked with immunosuppressive myeloid biology. Its pipeline aims to alleviate tumor‑microenvironment immunosuppression and enhance immune activation, converting cold tumors into hot ones and providing new therapeutic options for patients.

NanoCellect Biomedical, Inc., established in 2009 and headquartered in San Diego, California, specializes in developing innovative flow cytometry and cell sorting solutions for life science researchers. The company's flagship product, the WOLF Cell Sorter, employs a unique closed fluid-path microfluidic cartridge to facilitate efficient cell sorting while mitigating biohazard risks and shear stress issues common in traditional methods. Their portfolio of affordable, compact, and user-friendly instruments and consumables caters to various applications such as drug discovery, single-cell omics, cloning, antibody discovery, and basic research, empowering biomedical scientists with simplified cellular analysis and sorting capabilities.

Shenzhen Anteland Technology Co., Ltd, founded in 2015, specializes in the research and development, manufacturing, and sales of laser direct imaging equipment. The company has made significant investments in R&D, achieving advanced capabilities in micro and submicron lithography technology, and has established itself as a leader in the innovative DFAI technology. Anteland's laser exposure machines are versatile and cater to multiple industries, offering various exposure areas, light sources, and laser modules. Their products are utilized in sectors such as textile, decal, label printing, package printing, glass, semiconductor, and photovoltaic applications, providing customers with high precision and power solutions.

Libra Therapeutics is a biotechnology company dedicated to developing novel disease-modifying therapeutics for neurodegenerative diseases. Its platform focuses on restoring cellular balance through small molecule drugs that attenuate the production of neurotoxic proteins, targeting conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates aimed at targeting and eliminating disease-causing proteins for the treatment of cancer, neurodegenerative diseases, and other conditions. The company's lead product candidate, CFT7455, is an orally bioavailable degrader targeting IKZF1/3, designed to treat multiple myeloma and various lymphomas. Additionally, C4 Therapeutics is advancing CFT8634, which targets BRD9 for synovial sarcoma and SMARCB1-deleted solid tumors, as well as programs targeting BRAF V600E and RET for genetically defined resistant solid tumors. The company employs its proprietary Degronimid platform, which utilizes small molecule binders to flag harmful proteins for degradation by the cellular proteasome system, allowing for the potential treatment of previously undruggable targets. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics engages in strategic collaborations to enhance its research and development efforts.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

Regenacy Pharmaceuticals is a Boston-based biopharmaceutical company founded in 2016 that develops therapies for peripheral neuropathies, hemoglobinopathies and certain oncology indications. Its approach centers on restoring normal protein function with oral, isoform-selective histone deacetylase inhibitors. The company is advancing drug programs that include ricolinostat to address sickle cell disease and beta-thalassemia, as well as additional HDAC inhibitor–based therapies for neuropathies and related conditions.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Its proprietary platform leverages computational biology, genomics, and metabolomics to identify specific metabolic alterations that support cancer growth. By creating small molecules that specifically target these reprogrammed metabolic processes, Metabomed aims to halt tumor progression while minimizing harm to surrounding healthy tissues. This innovative approach allows for quicker initiation of treatment and increases the likelihood of successful patient outcomes.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Decipher Biosciences, Inc. is a genomic information company focused on the development and commercialization of clinical tests for urologic cancers. The company specializes in providing genomic tests such as Decipher Prostate Biopsy, which analyzes tumor tissue to tailor treatment based on the metastatic potential of prostate cancer. Additionally, Decipher Bladder offers genomic subtyping for muscle-invasive bladder cancer, assisting healthcare providers in determining which patients may benefit from neoadjuvant chemotherapy before radical cystectomy. Founded in 2008 and headquartered in San Diego, California, Decipher Biosciences also operates a research and development center in Vancouver, Canada. The company is actively expanding its GRID database, which consists of over 70,000 whole transcriptome profiles, and collaborates with pharmaceutical companies to identify biomarkers for new therapeutic responses.

Mesa Biotech, Inc. is a San Diego-based company that specializes in the design, development, manufacturing, and commercialization of molecular diagnostic tests aimed at infectious diseases. Founded in 2015, the company has developed innovative products such as the Accula Dock, which manages critical testing parameters, and various Accula test cassettes for detecting influenza and respiratory syncytial virus. Mesa Biotech's technology simplifies DNA and RNA molecular testing, merging the convenience of point-of-care testing with the sensitivity and specificity typically associated with laboratory-based diagnostics. This enables healthcare professionals to obtain actionable, laboratory-quality results directly at the point of care, enhancing the efficiency of disease management and treatment. The company also operates a satellite testing laboratory in Santa Fe, New Mexico.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.